SCHEMBL5799166

SCHEMBL5799166

O=C(O)C1CCN(c2cccc(F)c2)CC1

nearest known ligand 0.58

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 12/20 0.58
BPTF Q12830 1/20 0.51
PDE4A P27815 1/20 0.50
PDE4B Q07343 1/20 0.50
PDE4C Q08493 1/20 0.50
PDE4D Q08499 1/20 0.50
PDK2 Q15119 1/20 0.50
TRPV1 Q8NER1 1/20 0.48
KDM4E B2RXH2 1/20 0.47
CYP2C19 P33261 1/20 0.47
NPY5R Q15761 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2557961 0.91 NOTUM (0.72) NOTUMBPTF
SCHEMBL15578214 0.84 HTR1A (0.58) NOTUMPDE4APDE4BPDE4CPDE4D
SCHEMBL5801907 0.83 NOTUM (0.57) NOTUMPDK2KDM4ECYP2C19NPY5R
SCHEMBL1573274 0.83 NOTUM (0.83) NOTUM
SCHEMBL28860182 0.82 TRPV1 (0.55) BPTFTRPV1NPY5R
SCHEMBL13722313 0.82 PDK2 (0.54) NOTUMBPTFPDK2TRPV1KDM4E
SCHEMBL6502769 0.82 SCN9A (0.59) NOTUM
SCHEMBL1222301 0.81 NOTUM (0.79) NOTUMKDM4ECYP2C19
SCHEMBL5800964 0.81 NOTUM (0.83) NOTUMTRPV1KDM4E
SCHEMBL5799563 0.81 NOTUM (0.58) NOTUMPDK2TRPV1KDM4ECYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006058338-A2 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-01 WO claimed
US-20060116368-A1 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-01 US claimed
EP-3658554-A1 DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE North & South Brother Pharmacy Investment Company Limited (CN) 2020-06-03 EP disclosed
WO-2019001396-A1 DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2019-01-03 WO disclosed
US-8314113-B2 Substituted dihydroquinazolines II AICURIS GMBH & CO. KG (DE) 2012-11-20 US disclosed
US-8314113-B2 Substituted dihydroquinazolines II AICURIS GMBH & CO. KG (DE) 2012-11-20 US disclosed
EP-1685123-B1 SUBSTITUTED DIHYDROQUINAZOLINES II BAYER HEALTHCARE AG (DE) 2009-08-19 EP disclosed
US-20070281953-A1 Substituted Dihydroquinazolines II BAYER HEALTHCARE AG (DE) 2007-12-06 US disclosed
US-20070281953-A1 Substituted Dihydroquinazolines II BAYER HEALTHCARE AG (DE) 2007-12-06 US disclosed
US-20060116368-A1 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-01 US disclosed
WO-2006058338-A2 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281953-A1 Substituted Dihydroquinazolines II EIF2AK2, QDPR, IRF3 NOTUM 2453/4885BPTF 2071/4885PDE4A 775/4885
US-20060116368-A1 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor VDAC1, TRPV1, HVCN1 NOTUM 3548/4885BPTF 4192/4885PDE4A 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.